Olema Pharmaceuticals, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Olema Pharmaceuticals hired Jason O'Byrne as Chief Financial Officer effective August 11, 2026, with annual base salary of $545,000, target bonus of 45% ($245,250), and equity grant of 650,000 stock options vesting over 4 years. Additionally, O'Byrne receives $250,000 sign-on bonus and $100,000 anniversary retention payment (both contingent on 12- and 24-month tenure respectively), with severance protections including 12 months base salary plus prorated bonus if terminated without cause outside change-of-control period, or 12 months base + full target bonus in change-of-control scenario.
Why this rating
Executive hire at clinical-stage biotech is routine; total year-one compensation (~$795k cash + options) is modest relative to $243M market cap and typical for CFO role. No material business impact disclosed.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.